Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. John Thorp, Obstetrics and Gynecology
Project Run Dates
10/24/2006 to 8/1/2010
Total Award Amount
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria.
Associated Publications and other materials
Study Report Detail on Clinical Trials.gov
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. via PubMed
Associated Award Numbers: A07-0688-002, A07-0688-003, A07-0688-004, A07-0688-005, A07-0688-006, A07-0688-007, A07-0688-008, A08-0275-002, A07-0688-009, A07-0688-010, A07-0688-011, A08-0275-003, A07-0688-012, A08-0275-004, A08-0275-005, A08-0275-006, A08-0275-007, A08-0275-008, A08-0275-009, A08-0275-010, A08-0275-011, A07-0688-013, A08-0275-012, A08-0275-013, A08-0275-014, A08-0275-015, A08-0275-016